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A B S T R A C T
Endogenous fibrinolysis might lead to hematoma progression in spontaneous intracerebral hemorrhage (ICH).
We studied plasma biomarkers of fibrinolysis and hemostasis in twenty-two patients with ICH and nine healthy
controls (HC) in a single-center study. Patients with ICH had significantly higher D-dimer and plasmin-al-
pha-2-antiplasmin complexes compared to HC. At baseline, patients with hematoma progression had higher
urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) and lower plasminogen
levels, compared to those with no progression. 24-hour and day-7 matrix metalloproteinase-9 (MMP-9) was sig-
nificantly increased in patients with hematoma progression.
© 2019
1. Introduction
Fibrinolysis is initiated by two major plasminogen activators, tis-
sue-type plasminogen activator and urokinase-type plasminogen activa-
tor in response to tissue injury1 and may contribute to hematoma ex-
pansion. Plasminogen activators had not been previously shown to be
associated with hematoma expansion in spontaneous intracerebral hem-
orrhage (ICH) to the best of our knowledge.
In the Tranexamic acid for IntraCerebral Hemorrhage-2 (TICH-2)
trial, patients who were treated with tranexamic acid had a significant
reduction of hematoma expansion.2 In this sub-study, we explored if fib-
rinolysis plays a role in hematoma expansion by studying several plasma
biomarkers.
We explored if there were differences in plasma biomarkers be-
tween healthy controls (HC) and ICH patients; and between ICH pa
Abbreviations: HC, healthy controls; ICH, intracerebral hemorrhage; MMP-2, matrix
metalloproteinase-2; MMP-9, matrix metalloproteinase-9; PAP, plasmin-alpha-2-antiplas-
min complex; TAT, thrombin-antithrombin complex; tPA, tissue-type plasminogen activa-
tor; uPA, urokinase-type plasminogen activator.
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tients with and without hematoma progression. We also assessed the ef-
fects of tranexamic acid on the plasma biomarkers.
2. Methods
This was a sub-study of the TICH-2 trial conducted in Notting-
ham City Hospital, United Kingdom. The TICH-2 was a randomized
placebo-controlled trial, which examined the efficacy and safety of
tranexamic acid in spontaneous ICH.2 Patients recruited into the trial
were eligible for the sub-study unless there was coagulopathy, systemic
hypotension, or admission to intensive care unit. In addition, HC who
were age- and sex-matched to the patients were recruited. HC were ex-
cluded if they had a stroke, ICH, venous thromboembolism or been hos-
pitalised in the preceding three months, or taken tranexamic acid or an
anticoagulant in the preceding seven days. Ethics approval was obtained
prior to commencement. Informed consent was obtained from all partic-
ipants.
Venous blood was collected using EDTA tubes at baseline (before
the first dose of tranexamic acid or placebo), 24-hour and day-7. For
HC, only one blood sample was obtained. Platelet-poor plasma samples
were obtained by centrifuging blood samples at 2000g for 10 min at 4 °C
within 30 min of venepuncture. Samples were aliquoted and stored at
−80 °C, then analyzed in batches.
Assays assessed tissue-type plasminogen activator (tPA; ab190812,
Abcam, Cambridge, UK), urokinase-type plasminogen activator (uPA;
ab119611, Abcam, Cambridge, UK), plasminogen (As
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sayMax, St Charles, US), plasmin-alpha-2-antiplasmin complex (PAP;
SKU:HPAPKT-COM, Molecular Innovations, Michigan, US), D-dimer
(ab196269, Abcam, Cambridge, UK), fibrinogen antigen (ab208036,
Abcam, Cambridge, UK), thrombin-antithrombin complex (TAT;
SEA831Hu, CloudClone, Texas, US), matrix metalloproteinase-2
(MMP-2; KHC3082, Invitrogen, California, US) and matrix metallopro-
teinase-9 (MMP-9; RK00217, ABclonal, Massachusetts, US). All assays
were ELISA assays and performed in duplicates according to suppliers’
protocol.
Hematoma progression was defined as an increase in hematoma vol-
ume on follow-up scan of >33% or >6 mL from baseline hematoma, or
when follow-up scans were not available, early neurological deteriora-
tion (≥4 points increase in NIHSS or drop in GCS of ≥2) or death before
24-hour clinical assessment.
Due to the small sample size, data were not normally distributed.
Non-parametric tests (Mann-Whitney U test) are used for statistical
analyses. Data are shown as median [interquartile range, IQR], p < 0.05
is considered significant and analyses were performed using SPSS ver-
sion 24.
3. Results
Twenty-two patients and nine HC were recruited. Plasma samples
were collected in all participants at baseline, 19/22 at 24-hour (86.4%, 3
patients died) and 16/22 on day-7 (72.7%, 5 died and one on end-of-life
care). There were no significant differences in the baseline character-
istics between ICH patients and HC (Table 1). Nine patients received
tranexamic acid while 13 received placebo. There were no differences in
baseline characteristics between treatment groups apart from a greater
proportion of lobar hemorrhage in the tranexamic acid group (Table 1).
There were higher baseline D-dimer and PAP levels in ICH patients com-
pared to HC but no significant differences in other baseline biomarkers
(Table 2).
Seven patients (31.8%) had hematoma progression including 3
(13.6%) with hematoma growth and 3 (13.6%) who died before
24-hours and one with neurological deterioration and died on day-5. Pa-
tients with hematoma progression had significantly higher baseline tPA
and lower plasminogen levels (Table 2). Median uPA level was 2 times
higher in the hematoma progression group (p = 0.053). At 24-hour, tPA
and uPA levels in the hematoma progression group declined to levels
similar to patients without hematoma progression and healthy controls
(Fig. 1). Plasminogen levels in hematoma progression group decreased
further at 24-hour before returning to baseline levels on day-7.
MMP-9 levels were similar between groups at baseline with levels
in patients with hematoma progression gradually increase at 24-hour
(270.8 [200.5–322.6] vs 97.3 [60.3–207.7] ng/mL; p = 0.012) and
day-7 (656.6 vs 131.8 ng/mL, p < 0.001). There were no significant dif-
ferences in other biomarkers between those who had hematoma progres-
sion and those had not at baseline, 24-hour and day-7.
There were no significant differences in biomarkers between tranex-
amic acid and placebo group apart from 24-hour plasminogen level,
which was lower in tranexamic acid group (Fig. 2).
4. Discussion
Elevated tPA and uPA, and reduced plasminogen levels at baseline
were associated with hematoma progression. Conversely, tPA, uPA and
plasminogen levels in patients who did not have hematoma progression
were similar to healthy controls. These results suggest plasminogen acti-
vators may play a role in hematoma progression in ICH.
Although ICH patients had higher D-dimer and PAP levels com-
pared to HC, the levels were not increased in patients with hematoma
progression. One possible explanation is that systemic activation of
the fibrinolytic system only occurs when there is intra
Table 1
Baseline characteristics of ICH patients who received tranexamic acid or placebo and
healthy controls.
Variables
Tranexamic
acid Placebo
All
ICH
Healthy
controls P*
Participants (N) 9 13 22 9
Age (years) 74.8 (13.9) 74.5
(9.5)
74.6
(11.2)
66.9
(13.7)
0.11
Sex (male) 3 (33.3 8 (61.5) 11
(50)
4 (44.4) 0.78
Medical history (%)
Prior stroke 0 (0) 2 (15.4) 2 (9.1) 0 (0) 0.35
Hypertension 4 (44.4) 8 (61.5) 12
(54.5)
3 (33.3) 0.28
Diabetes mellitus 2 (22.2) 4 (30.8) 6
(27.3)
1 (11.1) 0.33
Hypercholesterolemia 1 (11.1) 3 (23.1) 4
(18.2)
1 (11.1) 0.63
Ischemic heart disease 2 (22.2) 3 (23.1) 5
(22.7)
0 (0) 0.12
Atrial fibrillation 1 (11.1) 1 (7.7) 2 (9.1) 0 (0) 0.35
Previous venous
thromboembolism
1 (11.1) 0 (0) 1 (4.5) 0 (0) 0.52
Previous intracerebral
hemorrhage
1 (11.1) 0 (0) 1 (4.5) 0 (0) 0.52
Peripheral artery
disease
0 (0) 1 (7.7) 1 (4.5) 0 (0) 0.52
Prior antiplatelet
therapy
2 (22.2) 7 (53.8) 9
(40.9)
2 (22.2) 0.32
Prior statin 2 (22.2) 6 (46.2) 8
(36.4)
1 (11.1) 0.16
Glasgow Coma Scale 15 [12.5,
15]
14 [14,
15]
15
[14,
15]
– –
NIHSS 11 [2.5, 20] 14 [6.5,
21]
13.5
[5.75,
19.5]
– –
Hematoma location
(%) †
– –
Supratentorial deep 2 (22.2) 10
(76.9)
12
(54.5)
– –
Supratentorial
superficial
6 (66.7) 3 (23.1) 9
(40.9)
– –
Infratentorial 1 (11.1) 0 (0) 1 (4.5) – –
Intraventricular
hemorrhage
1 (11.1) 3 (23.1) 4
(18.2)
– –
Subarachnoid
extension
0 (0) 4 (30.8) 4
(18.2)
– –
Hematoma volume
(mL)
31.8 (43.1) 33.0
(46.8)
32.5
(44.2)
– –
Perihematomal edema
volume (mL)
13.5 (19.0) 16.7
(17.2)
15.4
(17.6)
– –
Data are number (%), median [interquartile range] or mean (standard deviation).
NIHSS = National Institute of Health Stroke Scale.
* Comparison of ICH participants and volunteers by Chi-squared, Mann-Whitney U or
Student t tests.
† Hematoma location differed between participants randomized to tranexamic acid
and placebo, p = 0.033.
ventricular or subarachnoid extension, as supported by two studies,
which showed significantly higher D-dimer and PAP in patients with
intraventricular or subarachnoid extension.3,4 Unfortunately we only
had 4 cases of intraventricular hemorrhage and subarachnoid exten-
sion so we cannot test this hypothesis. Alternatively, tPA and uPA
may have acted via a plasmin-independent pathway, e.g. upregula-
tion of MMP-9 leading to hematoma growth as shown in animal
UN
CO
RR
EC
TE
D
PR
OO
F
Z.K. Law et al. / Hemorrhagic Stroke xxx (xxxx) 1–5 3
Table 2
Comparison of baseline plasma biomarkers of patients with hematoma progression and no hematoma progression.
Biomarkers Healthy controls (n = 9) All ICH (n = 22) P Baseline
Hematoma progression (n = 7) No hematoma progression (n = 15) P*
tPA, pg/mL 3217.6 [2547.1–4083.3] 3688.0 [2646.4–6263.4] 0.49 6234.2 [4229–9251] 2801.0 [2398.0–4351] 0.010
uPA, pg/mL 338.9 [97.0–518.0] 245.9 [99.6–550.0] 0.90 555.7 [205.1–706.4] 203.8 [93.6–430.6] 0.053
Plasminogen, µg/mL 212.5 [182.0–249.4] 211.5 [194.7–273.1] 0.90 199.0 [176.7–208.0] 218.2 [202.6–317.6] 0.032
PAP, ng/mL 1.2 [0.9–1.5] 1.8 [1.1–2.4] 0.026 1.4 [1.0–2.6] 1.8 [1.7–2.3] 0.75
TAT, ng/mL 174.5 [159.3–196.3] 183.5 [169.9–200.5] 0.46 184.7 [175.1–196.4] 182.3 [141.4–220.3] 0.75
D-dimer, ng/mL 357.0 [189.5–425.5] 809.5 [417–1294.5] 0.002 673 [411–1279] 1012 [419–1299] 0.50
Fibrinogen, mg/mL 5.2 [2.2–8.1] 4.8 [3.3–7.2] 0.73 4.8 [3.9–11.9] 4.5 [3.0–6.7] 0.55
MMP-2, ng/mL 27.0 [23.0–30.0] 26.0 [20.5–27.5] 0.47 26.0 [22.0–27.0] 24.0 [19.8–29.8] 0.63
MMP-9, ng/mL 97.0 [77.2–134.4] 142.0 [81.1–199.6] 0.28 104.1 [24.4–200.8] 148.3 [86.1–199.2] 0.50
Data are median [interquartile range].
* Mann-Whitney U test is used for analysis. tPA = tissue-type plasminogen activator; uPA = urokinase-type plasminogen activator; PAP = plasmin-α2antiplasmin complex;
TAT = thrombin-antithrombin complex; MMP-2 & -9 = matrix metalloproteinases-2 & -9.
Fig. 1. Illustrates trend of tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), plasminogen and matrix metalloproteinase-9 (MMP-9) between baseline,
24-hour and day-7. *Indicates p < 0.05 on Mann-Whitney U test comparison between hematoma progression and no hematoma progression. There was no difference in all baseline,
24-hour and day-7 levels between the no hematoma progression group and healthy controls.
models.5 The progressive rise of MMP-9 levels in patients with
hematoma progression in the current study support this hypothesis.
Tranexamic acid inhibits tPA and uPA but higher doses of tranex-
amic acid paradoxically potentiate uPA action.6 In our study, there was
no difference in tPA and uPA levels at 24-hour, as the levels may have
naturally declined in both tranexamic acid and placebo groups by then.
The strength of this study is its novel findings of increased plas-
minogen activators in hematoma progression. A main limitation is that
it is exploratory in nature, and has a small sample size. Regression
analysis, which would have allowed us to account for effects of vari-
ables such as hematoma volume, was not feasible due to the
small sample size. Finally, due to the dynamic nature of spontaneous
ICH, repeated sampling within the first 24 hours might have picked up
more rapid changes in biomarker levels.
In conclusion, the role of uPA and tPA in hematoma progression in
ICH needs to be further explored with larger studies. If the relation is
proven significant, plasma biomarkers may have a role in targeting he-
mostatic treatment in ICH.
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Fig. 2. Comparison of baseline, 24-hour and day-7 plasma biomarkers in patients who were treated with tranexamic acid and placebo. There was no significant difference (all p > 0.05)
in all comparison except 24-hour plasminogen levels which were lower in tranexamic acid group (p = 0.004).
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